NovaBridge Biosciences announces expanded givastomig safety and efficacy data

NBP•2026-10-08

NovaBridge Biosciences said expanded safety and efficacy data for givastomig will be presented at the European Society for Medical Oncology 2026.

1. Data presentation

NovaBridge Biosciences announced that expanded safety and efficacy data for givastomig will be presented at the European Society for Medical Oncology 2026.

NovaBridge Biosciences announces expanded givastomig safety and efficacy data

1. Data presentation

Related News

Bitdeer tells readers to disregard earlier release on Malaysia AI facility capacity target

American Express says OCC penalty does not impact full-year 2026 guidance

American Express fined $350 million for insufficient anti-money laundering program

Blue Gold six-month net loss widens 12% to $8.78 million; general and administrative expenses jump to $9.31 million

Linde files Form 3 for Senior VP APAC Armando Botello